Clinical trial · Interventional
BMS-247550 in Treating Patients With Advanced Pancreatic Cancer
A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) Every 21 Days in Patients With Advanced Pancreas Cancer
NCT00016965CI-TRIAL-00011005completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have advanced pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ixabepilone | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed advanced pancreatic adenocarcinoma * Distant metastases OR * Locoregional disease that has failed or is not amenable to locoregional therapy * No de novo locoregional disease * No known brain metastases PATIENT CHARACTERISTICS: Age: * Adult Performance status: * Zubrod 0-1 Life expectancy: * Not specified Hematopoietic: * Absolute granulocyte count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * SGOT or SGPT no greater than 2.5 times ULN * Alkaline phosphatase less than 2.5 times ULN Renal: * Creatinine no greater than 1.5 mg/dL Cardiovascular: * No recent myocardial infarction, unstable angina, or life-threatening arrhythmia Other: * Not pregnant or nursing * Fertile patients must use effective contraception * No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I or II cancer in remission * No prior severe hypersensitivity reaction to drugs containing Cremophor EL * No active or uncontrolled infection * No severe psychiatric disorders PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior neoadjuvant, adjuvant, or primary immunotherapy for advanced pancreatic cancer * No concurrent anticancer immunotherapy Chemotherapy: * No prior neoadjuvant, adjuvant, or primary chemotherapy for advanced pancreatic cancer * No other concurrent anticancer chemotherapy Endocrine therapy: * No prior neoadjuvant, adjuvant, or primary hormonal therapy for advanced pancreatic cancer * No concurrent anticancer hormonal therapy Radiotherapy: * No prior neoadjuvant, adjuvant, or primary radiotherapy or chemoradiotherapy for advanced pancreatic cancer * Prior palliative radiotherapy allowed if at least 1 lesion remains outside of radiation field or at least 1 lesion has progressed since radiotherapy * No concurrent anticancer radiotherapy except palliative radiotherapy to non-target metastatic sites Surgery: * At least 2 weeks since prior surgery for pancreatic cancer and recovered Other: * No other concurrent anticancer therapy * No concurrent herbal or unconventional therapy (e.g., St. John's Wort)
References
Publications (1)
- RESULTWhitehead RP, McCoy S, Rivkin SE, Gross HM, Conrad ME, Doolittle GC, Wolff RA, Goodwin JW, Dakhil SR, Abbruzzese JL. A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs. 2006 Nov;24(6):515-20. doi: 10.1007/s10637-006-8440-x. PMID 16699973